NO941310L - Sammensetning og fremgangsmåte for behandling av hepatitt C - Google Patents
Sammensetning og fremgangsmåte for behandling av hepatitt CInfo
- Publication number
- NO941310L NO941310L NO941310A NO941310A NO941310L NO 941310 L NO941310 L NO 941310L NO 941310 A NO941310 A NO 941310A NO 941310 A NO941310 A NO 941310A NO 941310 L NO941310 L NO 941310L
- Authority
- NO
- Norway
- Prior art keywords
- thymosin
- hepatitis
- treatment
- composition
- immune system
- Prior art date
Links
- 208000005176 Hepatitis C Diseases 0.000 title 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 abstract 4
- 108010046075 Thymosin Proteins 0.000 abstract 3
- 102000007501 Thymosin Human genes 0.000 abstract 3
- 108010078233 Thymalfasin Proteins 0.000 abstract 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 abstract 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 abstract 1
- 229960004231 thymalfasin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Beans For Foods Or Fodder (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75954491A | 1991-09-13 | 1991-09-13 | |
PCT/US1992/007556 WO1993005806A1 (en) | 1991-09-13 | 1992-09-08 | Composition and method of treating hepatitis c |
Publications (2)
Publication Number | Publication Date |
---|---|
NO941310D0 NO941310D0 (no) | 1994-04-12 |
NO941310L true NO941310L (no) | 1994-04-12 |
Family
ID=25056052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO941310A NO941310L (no) | 1991-09-13 | 1994-04-12 | Sammensetning og fremgangsmåte for behandling av hepatitt C |
Country Status (23)
Country | Link |
---|---|
US (3) | US6001799A (cs) |
EP (1) | EP0603305B1 (cs) |
JP (1) | JP3228512B2 (cs) |
KR (1) | KR100254082B1 (cs) |
AT (1) | ATE152914T1 (cs) |
AU (1) | AU667327B2 (cs) |
CA (1) | CA2119006C (cs) |
CZ (1) | CZ286827B6 (cs) |
DE (1) | DE69219782T2 (cs) |
DK (1) | DK0603305T3 (cs) |
ES (1) | ES2103966T3 (cs) |
FI (1) | FI107879B (cs) |
GR (1) | GR3024025T3 (cs) |
HK (1) | HK1021687A1 (cs) |
HU (1) | HU221006B1 (cs) |
MX (1) | MX9205240A (cs) |
NO (1) | NO941310L (cs) |
RO (1) | RO111991B1 (cs) |
RU (1) | RU2104010C1 (cs) |
SG (1) | SG64897A1 (cs) |
TW (1) | TW224053B (cs) |
WO (1) | WO1993005806A1 (cs) |
ZA (1) | ZA926964B (cs) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW224053B (cs) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
SG64892A1 (en) * | 1992-02-06 | 1999-05-25 | Sciclone Pharmaceuticals | Method for treating hepatitis b carriers with minimal disease |
AU751199B2 (en) * | 1992-07-13 | 2002-08-08 | Government Of The United States Of America As Represented By The Secretary Of The Army | Composition and method of treating hepatitis B |
AU4671193A (en) * | 1992-07-13 | 1994-01-31 | Kenneth E. Sherman | Composition and method of treating hepatitis b |
CN1072961C (zh) * | 1993-03-05 | 2001-10-17 | 施塞克龙药品公司 | 治疗对干扰素治疗无反应者的丙型肝炎的方法 |
US6200952B1 (en) * | 1993-06-02 | 2001-03-13 | Sciclone Pharmaceuticals, Inc. | Combination therapy method for treating chronic hepatitis B |
TW249754B (cs) * | 1993-10-26 | 1995-06-21 | Alpha I Biomedicals Inc | |
PT731710E (pt) * | 1993-11-05 | 2003-09-30 | Sciclone Pharmaceuticals Inc | Composicoes contendo timosine alpha 1 destinadas ao tratamento de pacientes sofrendo duma doenca de figado descompensado |
JP3837769B2 (ja) * | 1995-06-12 | 2006-10-25 | 大塚製薬株式会社 | 抗ウイルス剤 |
WO1997031649A1 (en) * | 1996-02-28 | 1997-09-04 | Ifi Istituto Farmacoterapico Italiano S.P.A. | PHARMACEUTICAL COMPOSITIONS COMPRISING NATURAL HUMAN α-INTERFERON |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
WO2001092282A2 (en) | 2000-05-26 | 2001-12-06 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
US7208167B2 (en) * | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
AU8353601A (en) * | 2000-08-07 | 2002-02-18 | Sciclone Pharmaceuticals Inc | Treatment of hepatitis c with thymosin, interferon and ribavirin |
WO2002044717A1 (en) * | 2000-12-01 | 2002-06-06 | Cornell Research Foundation | Animal model for flaviviridae infection |
RU2211703C2 (ru) * | 2001-06-08 | 2003-09-10 | ООО НТЦ "Юпитер-2" | Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием |
WO2003026589A2 (en) * | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
CN1564693A (zh) * | 2001-10-05 | 2005-01-12 | 印特缪恩股份有限公司 | 治疗肝纤维化和丙型肝炎病毒感染的方法 |
US20050054845A1 (en) * | 2001-10-26 | 2005-03-10 | Rhode Island Hospital | Thymosin augmentation of genetic immunization |
UA80957C2 (en) * | 2001-11-01 | 2007-11-26 | Sciclone Pharmaceuticals Inc | Method of administering a thymosin alpha 1 peptide |
CA2476279A1 (en) * | 2002-02-14 | 2003-08-21 | Lieven J. Stuyver | Modified fluorinated nucleoside analogues |
AP2005003213A0 (en) | 2002-06-28 | 2005-03-31 | Univ Cagliari | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections. |
CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷 |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
PL374831A1 (pl) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | Zmodyfikowane proleki 2' i 3'-nukleozydowe do leczenia zakażeń Flaviviridae |
KR20050088079A (ko) | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이 |
JP5116972B2 (ja) | 2002-12-12 | 2013-01-09 | イデニクス(ケイマン)リミテツド | 2’−分枝ヌクレオシドの製造方法 |
GB0301879D0 (en) * | 2003-01-27 | 2003-02-26 | Regent Res Llp | HCV combination therapy |
JP4149296B2 (ja) * | 2003-03-26 | 2008-09-10 | 株式会社ルネサステクノロジ | 半導体記憶装置 |
CN100342907C (zh) * | 2003-03-28 | 2007-10-17 | 希克龙制药公司 | 胸腺素α1在制备用于治疗或预防哺乳动物中曲霉菌感染的药物组合物中的应用 |
CA2520400C (en) * | 2003-03-28 | 2013-02-19 | Sciclone Pharmaceuticals, Inc. | Treatment of aspergillus infections with thymosin alpha 1 |
US20100311656A1 (en) * | 2003-04-23 | 2010-12-09 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
EP2345657A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
PT1658302E (pt) * | 2003-07-25 | 2010-10-25 | Centre Nat Rech Scient | Análogos do nucleósido purina para o tratamento de doenças provocadas por flaviviridae incluindo hepatite c |
WO2005021007A1 (fr) * | 2003-08-28 | 2005-03-10 | Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' | Prevention et traitement de l'hepatite virale b |
KR20070011451A (ko) | 2004-05-05 | 2007-01-24 | 예일 유니버시티 | 신규의 항바이러스 헬리오크산틴 유사체 |
CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
AU2005285045B2 (en) | 2004-09-14 | 2011-10-13 | Gilead Sciences, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
JP4516863B2 (ja) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | 音声合成装置、音声合成方法及びプログラム |
WO2007075876A2 (en) | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
PL2012816T3 (pl) * | 2006-05-02 | 2012-11-30 | Sigma Tau Ind Farmaceuti | Zastosowanie tymozyny 1, samej lub w kombinacji z ptx3 lub gancyklowirem, do leczenia zakażenia cytomegalowirusem |
ES2288118B1 (es) * | 2006-05-10 | 2008-11-01 | Bcn Peptides, S.A. | Procedimiento para sintetizar timosinas. |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
TW200946541A (en) * | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
EP2349315A4 (en) * | 2008-10-08 | 2012-07-04 | Univ Miami | LYMPHOCYTE REGULATION AND APPLICATION |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
EP2376088B1 (en) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates |
US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
CN102458470B (zh) | 2009-05-08 | 2016-01-20 | 赛生制药有限公司 | 作为疫苗增强剂的α胸腺素肽 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
BR112012024884A2 (pt) | 2010-03-31 | 2016-10-18 | Gilead Pharmasset Llc | síntese estereosseletiva de ativos contendo fósforo |
CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US8809354B2 (en) | 2011-12-31 | 2014-08-19 | Sheikh Riazuddin | 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections |
CN103800293B (zh) * | 2012-11-09 | 2015-10-21 | 长春海悦药业有限公司 | 一种含有胸腺法新的药物组合物及其制剂 |
SI3650014T1 (sl) | 2013-08-27 | 2022-01-31 | Gilead Pharmasset Llc | Formulacija kombinacije dveh protivirusnih spojin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1216056B (it) * | 1988-03-11 | 1990-02-22 | Sclavo Spa | Composizioni farmaceutiche contenenti timosina alfa 1. |
US5273963A (en) * | 1991-03-29 | 1993-12-28 | The George Washington University | Compositions and methods for treating small cell and nonsmall cell lung cancers |
TW224053B (cs) * | 1991-09-13 | 1994-05-21 | Paul B Chretien |
-
1992
- 1992-03-16 TW TW081101971A patent/TW224053B/zh active
- 1992-09-08 SG SG1996006295A patent/SG64897A1/en unknown
- 1992-09-08 DE DE69219782T patent/DE69219782T2/de not_active Expired - Lifetime
- 1992-09-08 RU RU94022480A patent/RU2104010C1/ru active
- 1992-09-08 EP EP92919977A patent/EP0603305B1/en not_active Expired - Lifetime
- 1992-09-08 RO RO94-00409A patent/RO111991B1/ro unknown
- 1992-09-08 DK DK92919977.6T patent/DK0603305T3/da active
- 1992-09-08 HU HU9400758A patent/HU221006B1/hu not_active IP Right Cessation
- 1992-09-08 CA CA002119006A patent/CA2119006C/en not_active Expired - Lifetime
- 1992-09-08 AU AU26447/92A patent/AU667327B2/en not_active Ceased
- 1992-09-08 ES ES92919977T patent/ES2103966T3/es not_active Expired - Lifetime
- 1992-09-08 WO PCT/US1992/007556 patent/WO1993005806A1/en active IP Right Grant
- 1992-09-08 KR KR1019940700603A patent/KR100254082B1/ko not_active Expired - Fee Related
- 1992-09-08 HK HK98105712A patent/HK1021687A1/en not_active IP Right Cessation
- 1992-09-08 AT AT92919977T patent/ATE152914T1/de active
- 1992-09-08 CZ CZ1994551A patent/CZ286827B6/cs not_active IP Right Cessation
- 1992-09-08 JP JP50608393A patent/JP3228512B2/ja not_active Expired - Fee Related
- 1992-09-11 ZA ZA926964A patent/ZA926964B/xx unknown
- 1992-09-14 MX MX9205240A patent/MX9205240A/es not_active IP Right Cessation
-
1993
- 1993-03-05 US US08/027,500 patent/US6001799A/en not_active Expired - Lifetime
- 1993-11-04 US US08/145,660 patent/US5849696A/en not_active Expired - Lifetime
-
1994
- 1994-03-10 FI FI941133A patent/FI107879B/fi not_active IP Right Cessation
- 1994-04-12 NO NO941310A patent/NO941310L/no unknown
-
1997
- 1997-07-09 GR GR970401680T patent/GR3024025T3/el unknown
-
2007
- 2007-05-11 US US11/801,834 patent/US20070218033A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO941310D0 (no) | Sammensetning og fremgangsmåte for behandling av hepatitt C | |
DK0380230T3 (da) | Immunogene sammensætninger mod gastrin-peptider | |
NO951340L (no) | Fremgangsmåte til å behandle lungesykdom med uridintrifosfater | |
FR2709966B1 (fr) | Vaccin pour la prévention du syndrome respiratoire et de la reproduction du porc. | |
DE69329558D1 (de) | Verfahren zur Behandlung von Multiplesklerose | |
FI943028L (fi) | Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi | |
SG46620A1 (en) | Method and composition foor the treatment of autoimmune hepatitis | |
EP0627930A4 (en) | COMPOSITION AND METHOD FOR TREATING HEPATITIS B. | |
FI941705A7 (fi) | Menetelmä viruspatogeenien läpipääsyn estämiseksi | |
ATE76579T1 (de) | Interferon-zusammensetzungen. | |
GR3024907T3 (en) | Antivenom immunesera | |
NO910219L (no) | Behandling av tre og trebaserte materialer. | |
EP0452360A4 (en) | Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections | |
DE3884652D1 (de) | Gate-Ausschaltthyristor und Verfahren zu dessen Herstellung. | |
ATE107166T1 (de) | Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration. | |
NO933628D0 (no) | Fremgangsmaate og blanding for behandling av herpes-infeksjoner | |
MY110041A (en) | Composition and method of treating hepatitis c | |
DK0497356T3 (da) | Sammensætninger og fremgangsmåde til tumorer i blødt væv | |
NO961775L (no) | Fremgangsmåte og sammensetning for behandling av pasienter med dekompensert leversykdom | |
ZA897105B (en) | Method and composition for the treatment of viral infections | |
NO903504L (no) | Doseringsbeholder for opptak og levering av midler for behandling av toey. | |
NO930550L (no) | Metode og preparat for behandling av virale infeksjoner | |
NO910474L (no) | Oppvarmet transportoer og metode for desinfisering av forurenset sykehus-avfall med liten stoerrelse. | |
GB9112552D0 (en) | Method and composition for the treatment of cancer | |
SE9101471D0 (sv) | Foerfarande foer tillverkning av byggelement och byggelement tillverkat enligt foerfarandet |